Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, randomised, controlled, parallel group study for the evaluation of safety and efficacy of Diclofenac HPBCD 75 mg ampoules s.c. in comparison with Diclofenac HPBCD 75 mg ampoules i.m. and Voltaren 75 mg ampoules i.m. in the treatment of acute moderate to severe pain following minor orthopaedic surgery.

Trial Profile

Open-label, randomised, controlled, parallel group study for the evaluation of safety and efficacy of Diclofenac HPBCD 75 mg ampoules s.c. in comparison with Diclofenac HPBCD 75 mg ampoules i.m. and Voltaren 75 mg ampoules i.m. in the treatment of acute moderate to severe pain following minor orthopaedic surgery.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diclofenac (Primary)
  • Indications Postoperative pain
  • Focus Adverse reactions
  • Acronyms DIRECT
  • Sponsors IBSA

Most Recent Events

  • 22 Mar 2013 New source identified and integrated (ISRCTN: Current Controlled Trials; 78851459).
  • 02 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top